Vertex Pharmaceuticals is a biotechnology company that invests in scientific innovation to create medicines for people with cystic fibrosis. It markets TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its pipeline includes a pipeline for Alpha-1 antitrypsin deficiency; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency; and VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and other serious kidney diseases.